First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations.
- DOI
- 10.1182/blood.2025032833
- Published
- 2026 Sep 17
- Container
- Blood
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1182/blood.2025032833,
title = {First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations.},
author = {Wang M and Hoffmann M and Wrobel T and Trneny M and Belada D and Demirkan F and Panayiotidis P and Jurczak W and Zinzani PL and Keating MM and Yoon SS and Egyed M and Tam CS and Johnson NA and Szafer-Glusman E and Lin J and Dean JP and Neuenburg JK and von Keudell G},
year = {2026},
journal = {Blood},
doi = {10.1182/blood.2025032833},
url = {https://doi.org/10.1182/blood.2025032833}
}RIS
TY - JOUR TI - First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations. AU - Wang M AU - Hoffmann M AU - Wrobel T AU - Trneny M AU - Belada D AU - Demirkan F AU - Panayiotidis P AU - Jurczak W AU - Zinzani PL AU - Keating MM AU - Yoon SS AU - Egyed M AU - Tam CS AU - Johnson NA AU - Szafer-Glusman E AU - Lin J AU - Dean JP AU - Neuenburg JK AU - von Keudell G PY - 2026 JO - Blood DO - 10.1182/blood.2025032833 UR - https://doi.org/10.1182/blood.2025032833 ER -
APA
M, W., M, H., T, W., M, T., D, B., F, D., P, P., W, J., PL, Z., MM, K., SS, Y., M, E., CS, T., NA, J., E, S., J, L., JP, D., JK, N., & G, V. K. (2026). First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations.. Blood. https://doi.org/10.1182/blood.2025032833
Source records
- pubmed · retrieved 2026-09-25T23:57:03.056Z